Controlled study of hypertransfusion during remission induction in childhood acute lymphocytic leukaemia.
In a prospective, controlled trial 26 anaemic, neutropenic children with newly diagnosed acute lymphocytic leukaemia were randomised in pairs to receive either transfusion to a haemoglobin of 10--12 g/dl where clinically indicated (group A) or hypertransfusion to a haemoglobin of 16--18 g/dl (group B). Compared with group A (11 of 13 transfused), group B (all transfused) had a significantly more rapid rise in neutrophils at 7 and 10 days post-transfusion, a lower incidence of infection, and less interruption to chemotherapy. Hypertransfusion restored the myeloid/erythroid ratio to normal in bone-marrow of 5 of 6 children and the proportion of early myeloid precursors was greater than in controls.
D000293:Adolescent; D000380:Agranulocytosis / Q000628:therapy*; D001803:Blood Transfusion; D002452:Cell Count; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004921:Erythropoietin / Q000097:blood; D005260:Female; D006412:Hematopoietic Stem Cells / Q000473:pathology; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007223:Infant; D017053:Infection Control; D007945:Leukemia, Lymphoid / Q000097:blood*; D007958:Leukocyte Count; D008297:Male; D009503:Neutropenia / Q000097:blood / Q000628:therapy*; D009504:Neutrophils / Q000473:pathology; D011446:Prospective Studies; D011897:Random Allocation; D012075:Remission, Spontaneous
D006454:Hemoglobins; D004921:Erythropoietin